STOK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stoke Therapeutics Inc (STOK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's promising drug pipeline, positive analyst sentiment, strong financial growth trends, and favorable options data support this decision. While the stock is slightly down today, the long-term potential outweighs short-term fluctuations.
The stock shows mixed technical signals. MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 41.867, suggesting no overbought or oversold conditions. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the current price is near a key support level (S1: 33.205), which may provide a good entry point.
Positive study data for Zorevunersen, showing disease-modifying potential for Dravet syndrome.
Analyst ratings are overwhelmingly positive, with price targets ranging from $36 to $
Financial growth trends are strong, with revenue up 117.25% YoY and net income losses narrowing by 45.09%.
The stock is currently down 2.89% in regular trading and 0.66% in pre-market trading, reflecting short-term bearish sentiment.
MACD indicates bearish momentum, and the stock has a 40% chance of declining in the next month based on historical patterns.
In Q3 2025, Stoke Therapeutics reported a 117.25% YoY revenue increase to $10.63M, a 45.09% improvement in net income to -$38.35M, and a 38.30% YoY increase in EPS to -0.65. Gross margin remained at 100%. These figures indicate strong growth trends despite ongoing losses, which are typical for biotech companies in the development phase.
Analysts are highly bullish on STOK. Wolfe Research initiated coverage with an Outperform rating and a $40 price target. Guggenheim sees a $60 price target, citing the transformative potential of Zorevunersen. Canaccord and H.C. Wainwright have raised their price targets to $36 and $50, respectively, following positive clinical data.
